NASDAQ:SUPN
Supernus Pharmaceuticals Stock News
$27.12
+0.550 (+2.07%)
At Close: May 31, 2024
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
08:00am, Monday, 22'nd Feb 2021
ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
09:00am, Monday, 08'th Feb 2021
ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
A Trio of High Earnings Return Stocks
10:51am, Sunday, 10'th Jan 2021
If you pick securities whose earnings return is more than twice that of the 20-year high-quality market corporate bonds, you could increase your probability to unearth value opportunities, in my opini
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
05:29pm, Wednesday, 06'th Jan 2021
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra
Sizing Up Supernus Pharmaceuticals
02:54pm, Wednesday, 30'th Dec 2020
It has been eight months since we last looked in on a promising biopharma concern named Supernus Pharmaceuticals. Some significant news has posted since then including some recently disclosed encourag
Why Supernus Pharmaceuticals Stock Is Rising Today
02:28pm, Wednesday, 23'rd Dec 2020
The company announced positive results from a clinical trial.
Supernus Stock Soars on Experimental ADHD Drug Update
11:49am, Wednesday, 23'rd Dec 2020
The shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) are up 17.7% at $26.50 at last check, after its experimental drug for attention deficit hyperactivity disorder (ADHD), SPN-812, met its main go
Supernus stock surges after ADHD-drug study results
06:53pm, Tuesday, 22'nd Dec 2020
Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hyperactiv
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
06:07pm, Tuesday, 22'nd Dec 2020
ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra
Supernus to Participate in Annual Piper Sandler Healthcare Conference
10:00pm, Wednesday, 18'th Nov 2020
ROCKVILLE, Md., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
06:30pm, Monday, 09'th Nov 2020
ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
01:56pm, Wednesday, 04'th Nov 2020
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call Transcript
Supernus Announces Third Quarter 2020 Financial Results
04:30pm, Tuesday, 03'rd Nov 2020
ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra
Supernus to Host Third Quarter 2020 Financial Results Conference Call
05:30pm, Tuesday, 27'th Oct 2020
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of centra
